A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Trial Profile

A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LixiLan-L
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Feb 2018 Results of post hoc analysis assessing the efficacy of iGlarLixi compared with iGlar alone in 30-week completers published in the Diabetes Therapy
    • 09 Dec 2017 Results of an analysis comparing the results of the LixiLan and DUAL clinical development programmes, presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 08 Dec 2017 Results of post hoc analysis of LixiLan-L and LixiLan-O trials assessing frequency and timings of gastrointestinal adverse events presented at the 2017 Congress of the International Diabetes Federation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top